December 12, 2025

Stephen Brady
Chief Executive Officer
Tempest Therapeutics, Inc.
2000 Sierra Point Parkway, Suite 400
Brisbane, CA 94005

       Re: Tempest Therapeutics, Inc.
           Registration Statement on Form S-1
           Filed December 9, 2025
           File No. 333-292026
Dear Stephen Brady:

       We have conducted a limited review of your registration statement and
have the
following comment.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
General

1.     We note your disclosure in the Form 8-K filed November 19, 2025,
incorporated by
       reference into the registration statement, that as a result of an Asset
Purchase
       Agreement with Erigen LLC and Factor Bioscience Inc., the company will
acquire all
       rights, title and interest to four therapeutic assets. We further note
that
       Erigen is expected to own 65% of the company on a fully-diluted basis;
and the Co-
       Founder, Chairman and Chief Executive Officer of Factor will become the
company   s
       Chief Executive Officer and President. We also note the Asset Purchase
Agreement
       states you will receive funding from Factor of up to $20 million over
18-months
       pursuant to a commitment letter. Please revise to provide carveout
financial
       statements for Erigen and/or Factor, including pro forma financial
statements.
 December 12, 2025
Page 2

       Alternatively, please tell us why these financial statements are not
required. Refer to
       Rule 11-01(d) of Regulation S-X.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Daniel Crawford at 202-551-7767 or Laura Crotty at
202-551-7614
with any other questions.



                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences
cc:   Jaime Chase, Esq.